Cyteir Therapeutics Valuation
| CYTDelisted Stock | USD 2.76 0.01 0.36% |
Based on Macroaxis valuation methodology, the firm appears to be overvalued. Cyteir Therapeutics shows a prevailing Real Value of $2.13 per share. The current price of the firm is $2.76. Our model approximates the value of Cyteir Therapeutics from analyzing the firm fundamentals such as Return On Equity of -0.24, current valuation of (20.89 M), and Shares Owned By Insiders of 6.63 % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Cyteir Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of Cyteir Therapeutics is based on 3 months time horizon. Increasing Cyteir Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Cyteir Therapeutics' intrinsic value may or may not be the same as its current market price of 2.76, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.76 | Real 2.13 | Hype 2.76 |
The intrinsic value of Cyteir Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Cyteir Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Cyteir Therapeutics helps investors to forecast how Cyteir stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cyteir Therapeutics more accurately as focusing exclusively on Cyteir Therapeutics' fundamentals will not take into account other important factors: Cyteir Therapeutics Total Value Analysis
Cyteir Therapeutics is currently anticipated to have company total value of (20.89 M) with market capitalization of 108.71 M, debt of 889 K, and cash on hands of 166.4 M. The negative valuation of Cyteir Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial commitments of the company both on and off balance sheet. Investors should carefully check all of the Cyteir Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(20.89 M) | 108.71 M | 889 K | 166.4 M |
Cyteir Therapeutics Asset Utilization
One of the ways to look at asset utilization of Cyteir is to check how much profit was generated for every dollar of assets it reports. Cyteir Therapeutics shows a negative utilization of assets of -0.14 percent, losing $0.00145 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Cyteir Therapeutics shows how discouraging it operates for each dollar spent on its assets.Cyteir Therapeutics Ownership Allocation
Cyteir Therapeutics holds a total of 36 Million outstanding shares. The majority of Cyteir Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Cyteir Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Cyteir Therapeutics. Please pay attention to any change in the institutional holdings of Cyteir Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Cyteir Therapeutics Profitability Analysis
Reported Net Loss for the year was (33.22 M) with loss before taxes, overhead, and interest of (16.59 M).About Cyteir Therapeutics Valuation
The delisted stock valuation mechanism determines Cyteir Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Cyteir Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Cyteir Therapeutics. We calculate exposure to Cyteir Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Cyteir Therapeutics's related companies.Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. The company was incorporated in 2012 and is based in Lexington, Massachusetts. Cyteir Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 40 people.
Cyteir Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Cyteir Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 35.3 M | |
| Shares Float | 10.8 M |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Other Consideration for investing in Cyteir Stock
If you are still planning to invest in Cyteir Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cyteir Therapeutics' history and understand the potential risks before investing.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |